Impact of Muscarinic M 3 Receptor Antagonism on the Risk of Type 2 Diabetes in Antidepressant-Treated Patients : A Case-Controlled Study
暂无分享,去创建一个
[1] U. Krus,et al. Altered serotonin (5-HT) 1D and 2A receptor expression may contribute to defective insulin and glucagon secretion in human type 2 diabetes , 2015, Peptides.
[2] M. Irizarry,et al. Incidence of type 2 diabetes among patients exposed to the combination of pravastatin and paroxetine. , 2015, Current drug safety.
[3] Sang Won Seo,et al. Effect of Psychotropic Drugs on Development of Diabetes Mellitus in Patients With Alzheimer's Disease , 2015, Medicine.
[4] I. Umar,et al. Age-dependent alteration of antioxidant defense system in hypertensive and type-2 diabetes patients , 2015, Journal of Diabetes & Metabolic Disorders.
[5] Xia Yang,et al. Shared Molecular Pathways and Gene Networks for Cardiovascular Disease and Type 2 Diabetes Mellitus in Women Across Diverse Ethnicities , 2014, Circulation. Cardiovascular genetics.
[6] U. Sambamoorthi,et al. Use of antidepressants and statins and short-term risk of new-onset diabetes among high risk adults. , 2014, Diabetes research and clinical practice.
[7] Varsha G. Vimalananda,et al. Depressive Symptoms, Antidepressant Use, and the Incidence of Diabetes in the Black Women’s Health Study , 2014, Diabetes Care.
[8] Xiao-dong Liu,et al. Co-administration of paroxetine and pravastatin causes deregulation of glucose homeostasis in diabetic rats via enhanced paroxetine exposure , 2014, Acta Pharmacologica Sinica.
[9] M. Lai,et al. Long-term antidepressant use and the risk of type 2 diabetes mellitus: a population-based, nested case-control study in Taiwan. , 2014, The Journal of clinical psychiatry.
[10] N. Maclaren,et al. Etiology and Pathogenesis of Diabetes Mellitus IN Children , 2013 .
[11] Li An,et al. Co‐medication of pravastatin and paroxetine—A categorical study , 2013, Journal of clinical pharmacology.
[12] Xu-Feng Huang,et al. Second Generation Antipsychotic-Induced Type 2 Diabetes: A Role for the Muscarinic M3 Receptor , 2013, CNS Drugs.
[13] U. Sambamoorthi,et al. Antidepressant use, depression, and new‐onset diabetes among elderly Medicare beneficiaries (在老年医疗保险受益者中调查抗抑郁药的使用、抑郁症以及新发糖尿病) , 2013, Journal of diabetes.
[14] Maarten J Postma,et al. The population-based prescription database IADB.nl: its development, usefulness in outcomes research and challenges , 2013, Expert review of pharmacoeconomics & outcomes research.
[15] G. Remington,et al. Atypical antipsychotics and effects of adrenergic and serotonergic receptor binding on insulin secretion in-vivo: An animal model , 2013, Schizophrenia Research.
[16] Kunihiro Suzuki,et al. Cell-Based Screening Identifies Paroxetine as an Inhibitor of Diabetic Endothelial Dysfunction , 2013, Diabetes.
[17] E. Mannucci,et al. Depression as a risk factor for diabetes: a meta-analysis of longitudinal studies. , 2013, The Journal of clinical psychiatry.
[18] J. P. Wilson,et al. Use of antidepressant agents and the risk of type 2 diabetes , 2011, European Journal of Clinical Pharmacology.
[19] S. M. Setter,et al. Drug-Induced Glucose Alterations Part 1: Drug-Induced Hypoglycemia , 2011, Diabetes Spectrum.
[20] P. de Jonge,et al. Depressive disorder and incident diabetes mellitus: the effect of characteristics of depression. , 2010, The American journal of psychiatry.
[21] H. Kendig,et al. Diabetes incidence associated with depression and antidepressants in the Melbourne Longitudinal Studies on Healthy Ageing (MELSHA) , 2009, International journal of geriatric psychiatry.
[22] S. Suissa,et al. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. , 2009, The American journal of psychiatry.
[23] A. Egberts,et al. No increased incidence of diabetes in antidepressant users , 2007, International clinical psychopharmacology.
[24] M. Tancer,et al. Metabolic syndrome: relevance to antidepressant treatment. , 2006, Journal of psychiatry & neuroscience : JPN.
[25] M. Keshavan,et al. Critical role of M3 muscarinic receptor in insulin secretion: implications for psychopharmacology. , 2006, Journal of clinical psychopharmacology.
[26] S. Kennedy,et al. The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms , 2006, Expert opinion on drug safety.
[27] H. Tobi,et al. Identifying parents in pharmacy data: a tool for the continuous monitoring of drug exposure to unborn children. , 2004, Journal of clinical epidemiology.
[28] S. Wild,et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.
[29] E. Richelson,et al. Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics. , 1993, Biochemical pharmacology.
[30] E H Wagner,et al. A chronic disease score from automated pharmacy data. , 1992, Journal of clinical epidemiology.
[31] J. Manson,et al. Use of antidepressant medication and risk of type 2 diabetes: results from three cohorts of US adults , 2011, Diabetologia.
[32] R. Holman,et al. Initial management of blood glucose in type 2 diabetes mellitus , 2010 .
[33] R. Hardy,et al. Depressive symptoms and risk of type 2 diabetes in a national sample of middle-aged and older adults. The English Longitudinal Study of Aging. Running Title: Depressive symptoms and incident diabetes , 2010 .
[34] K. Takeuchi,et al. Possible involvement of endogenous 5-HT in aggravation of cerulein-induced acute pancreatitis in mice. , 2007, Journal of pharmacological sciences.